Abstract:ObjectivesTo explore the expression level, association with disease activity and clinical significance of hsa_circ_0008301 in the peripheral blood of patients with primary Sjögren's syndrome (pSS).MethodsWe selected 70 pSS patients hospitalized under the Rheumatology service line at the General Hospital of Ningxia Medical University from September 2018 to June 2021 as the disease group, in which general data and clinical indicators were collected. Fifty-three patients with healthy physical examinations for the same period were selected as the healthy control group, and 32 patients with non-pSS rheumatic diseases were selected as the disease control group. We collected peripheral blood samples and used fluorescence quantitative PCR to detect the expression level of hsa_circ_0008301. In addition, we analyzed the association of the expression level of hsa_circ_0008301 with the clinical characteristics and disease activity of pSS patients. A receiver operating characteristic curve was used to evaluate the diagnosis and the disease activity value of hsa_circ_0008301 in patients with pSS. Meanwhile, we analyzed the differential expression of hsa_circ_0008301 in 24 pSS patients selected from the disease group before and after treatment.ResultsThe relative expression of hsa_circ_0008301 in the peripheral blood of pSS patients was significantly higher than that in the control groups including healthy control group and disease control group. The expression level of hsa_circ_0008301 was high in pSS patients with a course of disease ≥ 10 years, fatigue symptoms, platelets 16 g/L, complement C3 < 0.9 g/L, ESSDAI score ≥ 5 and positively correlated with the above groups. Furthermore, ROC analysis showed that hsa_circ_0008301 was statistically significant between pSS patients and healthy controls. We selected patients from the disease group before and after treatment and showed that the expression level of hsa_circ_0008301 decreased significantly after treatment, compared with before. The area under the curve (AUC) was 0.825 (95% CI: 0.754 ∼ 0.897; P 0.0420, and the maximum Youden index was 0.337. In addition, ROC analysis revealed that hsa_circ_0008301 was statistically significant between disease-active patients and stable patients. The AUC value was 0.681 (95% CI: 0.553 ∼ 0.809; P = 0.010), the sensitivity was 65.90%, the specificity was 72.40%, the optimal truncation value was > 0.0285, and the maximum Youden index was 0.383. ROC analysis indicated that hsa_circ_0008301 has some value in the diagnosis and disease activity of patients with pSS. Comparison of 24 pSS patients selected from the disease group before and after treatment showed that the expression level of hsa_circ_0008301 decreased significantly after treatment compared with before treatment (Z = − 4.257, P < 0.0001). ROC analysis indicated that hsa_circ_0008301 has some value in the diagnosis and disease activity of patients with pSS.ConclusionsHsa_circ_0008301 is expressed in higher levels in the peripheral blood of patients with pSS, which is related to the disease activity. It may be involved in the occurrence and development of pSS and may have a potential biomarker for the disease.

Expression of miR-146a in primary Sjgren’s syndrome

Mir‐146a and Mir‐155 Expression in PBMCs from Patients with Sjögren's Syndrome

MicroRNA Profiling in Chinese Patients with Primary Sjögren Syndrome Reveals Elevated Mirna-181A in Peripheral Blood Mononuclear Cells.

Expression of FcγRⅡb on peripheral B cells and its clinical significance in patients with primary Sj(o)gren's syndrome

[The Expression of Interferon-Alpha in Peripheral Blood of Patients with Primary Sjogren's Syndrome].

TNF Receptor-Associated Factor 6 Expression in Peripheral Blood Mononuclear Cells of Patients with Primary Sjgren’s Syndrome and Its Clinical Significance

Frequency and significance of CD4~+CD25~+CD127~(low/-) T cells in the peripheral blood of patients with primary Sjgren's syndrome

Differential long non-coding RNA expression profile and function analysis in primary Sjogren’s syndrome

LncRNA and mRNA expression profile of peripheral blood mononuclear cells in primary Sjögren’s syndrome patients

Increased Expression of T Cell Immunoglobulin and Mucin-3 in Peripheral Blood Mononuclear Cells from Patients with Primary Sj¨ogren’s Syndrome and Its Clinical Significance

Hsa_circ_0008301 as a potential biomarker of disease activity for primary Sjogren's syndrome: Increased expression in peripheral blood of patients with primary Sjogren's syndrome

Expression of microRNA on peripheral blood cells in patients with systemic lupus erythematosus

Differential Expression of Mir-17-92 Cluster among Varying Histological Stages of Minor Salivary Gland in Patients with Primary Sjögren's Syndrome.

Expression and Significance of Mirna-31 in Peripheral Blood Mononuclear Cells of Rheumatoid Arthritis Patients

Expression and regulatory characteristics of peripheral blood immune cells in primary Sjögren's syndrome patients using single-cell transcriptomic.

Establishment of Fluorogenic Quantitative Method for Measurement of SSB Mrna Gene Expression in Sj(O)gren Syndrome Patients

Clinical analysis of the neurological involvement in primary Sj(o)gren's syndrome

microRNA-146a, TRAF6 gene and IRAK1 gene expressions in the peripheral mononuclear cells of patients with ankylosing spondylitis

Expression of B Lymphocyte Stimulator in the Renal Tissues of Patients with Primary Sj(o)gren Syndrome

Monocyte-derived dendritic cells from primary Sjgren′s syndrome patients were hypersensitive to polyinosinic polycytidylic acid stimulation

Peripheral neuropathy in primary Sj(o)gren's syndrome